BACKGROUND: Upregulation of the endo-beta-D-glucuronidase, heparanase, was noted in an increasing number of human malignancies. Heparanase expression correlated with enhanced local and distant metastatic spread, increased vascular density, and reduced postoperative survival. PATIENTS AND METHODS: We analyzed heparanase expression in 60 patients (aged 59 +/- 17 years) with malignant salivary tumors (39 males and 21 females) using immunohistochemistry. We applied antiheparanase antibody 733, which has previously been shown to preferentially recognize a 50-kDa active heparanase subunit over a 65-kDa latent enzyme. Thus, immunostaining can directly be correlated with enzymatic activity. RESULTS: Heparanase staining was positive (> 0) in 70% of tumors (42 of 60 patients) and was negative (0) in the remaining 30% (18 patients). The cumulative survival of patients diagnosed as heparanase-negative (n = 18) at 300 months was 70% (95% confidence interval = 35-88). In contrast, the cumulative survival of patients diagnosed as heparanase-positive (n = 42) at 300 months was 0% (statistically significant difference, P = .035). CONCLUSIONS: Heparanase expression levels inversely correlate with the survival rates of salivary gland cancer patients, clearly indicating that heparanase is a reliable prognostic factor for this malignancy and an attractive target for anticancer drug development.
BACKGROUND: Upregulation of the endo-beta-D-glucuronidase, heparanase, was noted in an increasing number of humanmalignancies. Heparanase expression correlated with enhanced local and distant metastatic spread, increased vascular density, and reduced postoperative survival. PATIENTS AND METHODS: We analyzed heparanase expression in 60 patients (aged 59 +/- 17 years) with malignant salivary tumors (39 males and 21 females) using immunohistochemistry. We applied antiheparanase antibody 733, which has previously been shown to preferentially recognize a 50-kDa active heparanase subunit over a 65-kDa latent enzyme. Thus, immunostaining can directly be correlated with enzymatic activity. RESULTS:Heparanase staining was positive (> 0) in 70% of tumors (42 of 60 patients) and was negative (0) in the remaining 30% (18 patients). The cumulative survival of patients diagnosed as heparanase-negative (n = 18) at 300 months was 70% (95% confidence interval = 35-88). In contrast, the cumulative survival of patients diagnosed as heparanase-positive (n = 42) at 300 months was 0% (statistically significant difference, P = .035). CONCLUSIONS:Heparanase expression levels inversely correlate with the survival rates of salivary gland cancerpatients, clearly indicating that heparanase is a reliable prognostic factor for this malignancy and an attractive target for anticancer drug development.
Authors: A Koliopanos; H Friess; J Kleeff; X Shi; Q Liao; I Pecker; I Vlodavsky; A Zimmermann; M W Büchler Journal: Cancer Res Date: 2001-06-15 Impact factor: 12.701
Authors: K Gohji; H Hirano; M Okamoto; S Kitazawa; M Toyoshima; J Dong; Y Katsuoka; M Nakajima Journal: Int J Cancer Date: 2001-09-20 Impact factor: 7.396
Authors: J Rohloff; J Zinke; K Schoppmeyer; A Tannapfel; H Witzigmann; J Mössner; C Wittekind; K Caca Journal: Br J Cancer Date: 2002-04-22 Impact factor: 7.640
Authors: Israel Vlodavsky; Phillip Beckhove; Immanuel Lerner; Claudio Pisano; Amichai Meirovitz; Neta Ilan; Michael Elkin Journal: Cancer Microenviron Date: 2011-08-03
Authors: Esti Cohen; Ilana Doweck; Inna Naroditsky; Ofer Ben-Izhak; Ran Kremer; Lael A Best; Israel Vlodavsky; Neta Ilan Journal: Cancer Date: 2008-09-01 Impact factor: 6.860